# Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

> **NCT00458536** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 38 (actual)

## Conditions studied

- Renal Cancer

## Interventions

- **BIOLOGICAL:** Dendritic Cell Tumor Fusion Vaccine
- **DRUG:** Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)

## Key facts

- **NCT ID:** NCT00458536
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2014-12
- **Final completion:** 2023-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458536, "Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00458536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*